SynthesisJournal of neurology2026
Effects of deep brain stimulation on non-motor symptoms in Parkinson's disease: insights from longitudinal studies using consistent evaluation scales.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDeep brain stimulation (DBS) is an effective treatment for motor symptoms in Parkinson's disease (PD). However, its effects on non-motor symptoms (NMS) have been rarely assessed due to inconsistencies in evaluation methods used in different studies. This meta-analysis aimed to assess the effects of DBS on NMS in PD using studies that employed consistent, standardized evaluation tools.
methodsA systematic review was conducted following the PRISMA guidelines. Longitudinal studies published between 2007 and 2024 were included if they evaluated bilateral DBS using identical NMS scales with involvement of at least six studies per tool. Assessment tools included the Beck Depression Inventory (BDI and BDI-II), the Hamilton Depression Rating Scale (HAMD), the Apathy Evaluation Scale (AES), the Epworth Sleepiness Scale (ESS), Parkinson's Disease Sleep Scale (PDSS), the Non-Motor Symptoms Scale (NMSS), the Mini-Mental State Examination (MMSE), and the Parkinson's Disease Questionnaire-39 (PDQ-39).
resultsNotably, 57 studies involving 3,200 patients were included. DBS significantly improved NMS, including depression (SMD:-0.19 to -0.35), sleep quality (PDSS SMD: 0.68; ESS SMD: - 0.32), and overall NMS (SMD: - 0.62). Moreover, quality-of-life was significantly improved (SMD: - 0.71), except in the communication domain. Although the levodopa equivalent daily dose (LEDD) was reduced by 49.2%, no significant correlation was found between LEDD reduction and quality-of-life improvement.
conclusionDBS could provide significant improvements in key NMS of PD, independent of reductions in LEDD. These findings revealed the direct neuromodulatory effects of DBS and highlighted its role in personalized treatment planning, particularly for patients with prominent depressive symptoms or sleep disturbances.
Indexed as
Identifiers
41511668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.